Combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)

US11406638B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Franziska Elena HERRMANN · Weilheim, DE
• Peter Nickolaus · Warthausen, DE
• Stefan Ludwig Michael WOLLIN · Bad Waldsee, DE

Key dates

• Filing date: Oct 22, 2018
• Grant date: Aug 9, 2022
• Expiry date: Oct 22, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P11/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitor of formula III or a pharmaceutically acceptable salt thereof.